ArticleCritical care (London, England)2020
Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?
Article in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04540926 (Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic
Who cites it
26 citing papers in PubMed.
- Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial.Scientific reports · 2026Trial
- Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study.Journal of internal medicine · 2021Trial
- Efficacy and safety of calcineurin inhibitors (CNIs) for septic patients in ICU: a cohort study from MIMIC database.Frontiers in pharmacology · 2024Article
- Improving the generalizability of protein-ligand binding predictions with AI-Bind.Nature communications · 2023Article
- An overview on the treatments and prevention against COVID-19.Virology journal · 2023Review
- Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review.World journal of critical care medicine · 2022Article
- An inductive graph neural network model for compound-protein interaction prediction based on a homogeneous graph.Briefings in bioinformatics · 2022Review
- Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP).Viruses · 2022Review
- Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.Microbiology spectrum · 2022Article
- Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection.Journal of personalized medicine · 2022Article
- Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: Insights from machine learning and bioinformatics approaches.Frontiers in immunology · 2022Article
- Assessment of COVID-19 vaccination among healthcare workers in Iraq; adverse effects and hesitancy.PloS one · 2022Article
- Targeting cathepsins: A potential link between COVID-19 and associated neurological manifestations.Heliyon · 2021Article
- Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action.Patterns (New York, N.Y.) · 2021Article
- A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing.Nature machine intelligence · 2021Article
- A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.Scientific data · 2021Article
- Review
- Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector.Advanced therapeutics · 2021Review
- Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?Frontiers in medicine · 2021Review
- Evaluation of the Pharmacologic Treatment of COVID-19 Pandemic in Iraq.Current pharmacology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.